Sichuan Biokin chases Hong Kong listing after BSM drug deal
The biopharma company has yet to market any products but one of its antibody-drug conjugates is being jointly developed in a lucrative collaboration with Bristol Myers Squibb Key Takeaways: Sichuan…
Recent Articles
RELATED ARTICLES
-
Akeso marks profit milestone with swift rights issue
9926.HK -
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
BeiGene’s aggressive expansion brings revenue jolt
BGNE.US 6160.HK 688235.SHG
